Gambro pushes forward into the Baltic with purchase of Lithuanian clinics:
This article was originally published in Clinica
Executive Summary
Gambro Healthcare has moved into the Lithuanian renal care market with the acquisition of 11 clinics, serving around 300 patients, for an undisclosed sum. According to the Swedish group, the Lithuanian dialysis services market consist of approximately 1,200 patients, of which half are treated privately and the remainder in public hospitals. While the purchase is expected to have a modest impact Gambro's bottom line, a presence in Lithuania should act as a springboard into the wider and emerging Baltic states market, says the company.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.